AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11094003
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline at 10 mL/h via a disposable infusion pump
Trial: 8054250
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg rac-ibuprofen
Trial: 8054250
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg rac-ibuprofen
Trial: 3047100
Drug: Triazolam 0.5
RxNorm normalized name: triazolam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam 0.5 mg nightly for 5 weeks
Trial: 31994303
Drug: 270 mg
RxNorm normalized name: leucine 270 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mg ferrous sulfate twice a day (total elemental iron dose: 160 mg / day)
Trial: 31994303
Drug: 270 mg
RxNorm normalized name: leucine 270 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mg ferrous sulfate once a day (total elemental iron dose: 80 mg / day)
Trial: 31994303
Drug: 270 mg
RxNorm normalized name: leucine 270 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mg ferrous sulfate every other day (total elemental iron dose: 80 mg / every other day)
Trial: 25922062
Drug: Mito-FLAG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mito-FLAG with Ara-C as bolus (1000 mg/m(2) over 1 h, every 12 h, days 1-5)
Trial: 25922062
Drug: Mito-FLAG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mito-FLAG with Ara-C as continuous infusion (150 mg/m(2) over 24 h, days 1-5)
Trial: 25922062
Drug: Mito-FLAG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mito-FLAG with Ara-C as continuous infusion
Trial: 23827771
Drug: Betamethasone +
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone + Essex® cream
Trial: 23827771
Drug: Essex® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essex® cream
Trial: 23827771
Drug: Canoderm® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canoderm® cream
Trial: 21062464
Drug: NRT oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT oral dose tailored by DNA analysis (OPRM1 gene) (genotype)
Trial: 21062464
Drug: NRT oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT oral dose tailored by nicotine dependence questionnaire score (phenotype)
Trial: 18476606
Drug: BCG-PSN 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-PSN 1.0 mg twice a week for two months
Trial: 18476606
Drug: Intranasal azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal azelastine twice a day as needed
Trial: 14658986
Drug: Long-term pharmacotherapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term pharmacotherapy
Trial: 14658986
Drug: Psychotherapy (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (alone or combined with medication)
Trial: 9534995
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccines
Trial: 6697786
Drug: Inhaled glycopyrrolate
RxNorm normalized name: glycopyrrolate Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glycopyrrolate (1.3 mg)
Trial: 6697786
Drug: Atropine (2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (2.6 mg)
Trial: 31525242
Drug: Mothers whose
RxNorm normalized name: Allium fistulosum whoe extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mothers whose household monthly income was more than $100
Trial: 29409494
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine Zengru Gao
Trial: 27045034
Drug: Fenretinide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (oral retinoid) for 2 years
Trial: 27045034
Drug: Baseline VEGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline VEGF levels in the top quintile (≥350 pg/mL)
Trial: 24578135
Drug: Neutralization of
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralization of Dkk1 using a monoclonal antibody after renal injury
Trial: 24578135
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Dkk1 antibody and phosphate binder therapy
Trial: 12208481
Drug: Pravastatin (CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (CC genotype)
Trial: 10206198
Drug: Expectant management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant management (no further treatment)
Trial: 2217010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiopentone and etomidate (5:1 ratio)
Trial: 2217010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiopentone and etomidate (13:1 ratio)
Trial: 2217010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiopentone and etomidate (25:1 ratio)
Trial: 6994960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified what treatment was used)
Trial: 27801706
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy + Calcium + Vitamin D (HT + Ca/D)
Trial: 25874723
Drug: HIV-DNA vaccine
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-DNA vaccine containing plasmids expressing HIV-1 gp160 subtypes A, B, C, Rev B, Gag A, B and RTmut B, followed by recombinant HIV-MVA boost expressing CRF01_AE HIV-1 Env subtype E and Gag-Pol subtype A.
Trial: 16418018
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg 1 hour before surgery, then 200 mg every 12 hours for the first 5 days
Trial: 9211578
Drug: Thiamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (5 g)
Trial: 9211578
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g lactose)
Trial: 8433254
Drug: Tetracycline HCl
RxNorm normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline HCl 50 mg/ml
Trial: 8433254
Drug: Tetracycline HCl
RxNorm normalized name: tetracycline HCl
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline HCl 10 mg/ml
Trial: 28892591
Drug: Etanercept 10
RxNorm normalized name: Etanercept 10 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 10 mg once-weekly
Trial: 28892591
Drug: Etanercept 10
RxNorm normalized name: Etanercept 10 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 10 mg twice-weekly
Trial: 28892591
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg every 2 weeks
Trial: 28892591
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg once-weekly
Trial: 27660305
Drug: Lung ultrasound-guided
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ultrasound-guided ultrafiltration prescription policy
Trial: 25068411
Drug: Lidocaine 3
RxNorm normalized name: Lidocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 3 mg/kg plus ketamine 50 mg
Trial: 20737642
Drug: Fenofibrate immediate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate immediate release (IR) tablet formulations
Trial: 20737642
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing sodium lauryl sulfate (SLS)
Trial: 1331992
Drug: lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lomefloxacin 400 mg
Trial: 1331992
Drug: ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 750 mg
Trial: 28674856
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antiglaucoma medications)
Trial: 27401892
Drug: onartuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onartuzumab (10 mg/kg) plus mFOLFOX6
Trial: 27401892
Drug: onartuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onartuzumab (10 mg/kg) plus mFOLFOX6 in MET-positive population
Trial: 18242415
Drug: Nutritious supplement
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritious supplement (atole)
Trial: 18242415
Drug: Less nutritious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less nutritious supplement (fresco)
Trial: 16193892
Drug: Avonex® (interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avonex® (interferon beta-la) 30 μg, intramuscular, once weekly
Trial: 10628579
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (tricyclic antidepressants, antiserotonin antidepressants, selective serotonin reuptake inhibitors, or multiple agents)
Trial: 2025805
Drug: Topical Xylocaine
RxNorm normalized name: Xylocaine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Xylocaine
Trial: 6277018
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg given twice daily for 4 weeks
Trial: 6277018
Drug: Ranitidine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine for a further 4-week period after initial treatment
Trial: 31936725
Drug: Once-weekly sprint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly sprint interval training (SIT)
Trial: 31936725
Drug: Twice-weekly sprint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly sprint interval training (SIT)
Trial: 15355358
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hydroquinone cream and sunscreens)
Trial: 7865920
Drug: Individual, direct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual, direct speech and language therapy (third group)
Trial: 30958045
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg octacosanol intake
Trial: 24890674
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream or ointment administered once or twice daily
Trial: 20940336
Drug: PI-2301 (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-2301 (0.035 to 60 mg subcutaneous injection)
Trial: 20940336
Drug: PI-2301 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-2301 (10, 30, and 60 mg cohorts)
Trial: 20940336
Drug: PI-2301 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-2301 (1, 3, or 10 mg)
Trial: 20940336
Drug: PI-2301 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI-2301 (30 or 60 mg)
Trial: 15236997
Drug: Early-hCG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-hCG group (10000 IU hCG administered as soon as at least three follicles were >=17 mm on ultrasound)
Trial: 15236997
Drug: Late-hCG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-hCG group (10000 IU hCG administered 2 days after the criterion was met)
Trial: 11585881
Drug: L&W with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L&W with tPA (4 mg)
Trial: 11585881
Drug: L&W with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L&W with urokinase (UK) (250,000 U)
Trial: 24320206
Drug: Bidirectional knotless
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidirectional knotless barbed suture (Quill™‐0; Angiotech Pharmaceuticals, Inc.)
Trial: 22078155
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (50 mg/mL, 5 mg per 0.1 mL, administered once in 1 nostril)
Trial: 22078155
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (2.5 mg, infused over 10 seconds)
Trial: 18653268
Drug: ARB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB treatment (valsartan, candesartan, losartan)
Trial: 7495191
Drug: Vigabatrin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin as add-on therapy
Trial: 1369725
Drug: Naftidrofuryl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (2 x 316.5 mg tablets daily with meals) for 6 months
Trial: 1369725
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets daily during washout and treatment)
Trial: 30709958
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) monotherapy for 3 months
Trial: 30709958
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline levels of tumor necrosis factor receptor I (TNF-RI)
Trial: 30709958
Drug: High baseline
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High baseline levels of vascular cell adhesion molecule 1 (VCAM-1)
Trial: 23645886
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 20 μg/day
Trial: 23645886
Drug: Ex-BID (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex-BID (twice-daily exenatide injections) 5 → 10 μg
Trial: 23645886
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 60 μg/day
Trial: 23645886
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 80 μg/day
Trial: 23645886
Drug: All ITCA
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All ITCA 650 groups except 20 → 20 μg/day
Trial: 19678443
Drug: Duraphat (Colgate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraphat (Colgate Oral Pharmaceuticals, Inc)
Trial: 15284257
Drug: FEC 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 100 (epirubicin 100 mg/m²)
Trial: 15284257
Drug: FEC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 50 (epirubicin 50 mg/m²)
Trial: 11528252
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) >500 million units total dose
Trial: 11528252
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) <=500 million units total dose
Trial: 11528252
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) >500 million units total dose in patients with histology F2 or F3
Trial: 19422759
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (olanzapine, quetiapine, risperidone) combined with SSRI and cognitive-behavioral therapy (CBT) for 1 year
Trial: 19422759
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) plus cognitive-behavioral therapy (CBT) for 1 year
Trial: 15385013
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg x kg(‐1) bolus followed by 100 microg x kg(‐1) x min(‐1) infusion)
Trial: 15385013
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mg x kg(‐1) bolus after 0.5 mg x kg(‐1) bolus of ketamine followed by 75 microg x kg(‐1) x min(‐1) infusion)
Trial: 11527684
Drug: Neoadjuvant regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy (etoposide, ifosfamide, doxorubicin)
Trial: 11527684
Drug: Neoadjuvant regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy
Trial: 1977089
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg nocte
Trial: 28501869
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) progesterone 50 mg in oil, single daily injection
Trial: 28501869
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone 200 mg micronized, 3 times daily
Trial: 20393026
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy (CRT) with 4 weeks' PSK administration
Trial: 18468761
Drug: Palatal mucoadhesive
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Palatal mucoadhesive tablet containing herbal formulation
Trial: 18468761
Drug: Herbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal formulation ingredients (sage, Echinacea, Lavender, Mastic gum)
Trial: 12917867
Drug: Home-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based therapy (n=34)
Trial: 10343785
Drug: lorazepam (0.038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam (0.038 mg kg‐1)
Trial: 1746465
Drug: Intracoronary diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary diltiazem (0.5 mg)
Trial: 1746465
Drug: Intracoronary diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary diltiazem (0.5 mg) with placebo pretreatment
Trial: 1746465
Drug: Intracoronary diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary diltiazem (0.5 mg) with isosorbide dinitrate pretreatment
Trial: 7102536
Drug: Propranolol (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10, 20, and 40 mg four times a day)
Trial: 7102536
Drug: Pindolol (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2.5, 5, and 10 mg four times a day)
Trial: 30143387
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride nasal gel at 6.0mg/g
Trial: 30143387
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride nasal gel at 4.5mg/g
Trial: 30143387
Drug: Both concentrations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both concentrations (6.0mg/g and 4.5mg/g)
Trial: 25022116
Drug: Acupuncture (warming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (warming needling manipulation at key acupoints Hegu (LI 4) and Taichong (LR 3), once a day for 10 treatments, 2 sessions total)
Trial: 25022116
Drug: Medication (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (2.5 mg diazepam tablets, three times a day for 23 days)
Trial: 20026538
Drug: Type of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type of antibiotic prophylaxis
Trial: 14707430
Drug: Olive oil-based
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil-based emulsion (0.16 g/kg/h for 3 hours)
Trial: 14707430
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil + medium chain fatty acid (MCT) emulsion (0.16 g/kg/h for 3 hours)
Trial: 11367869
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (intramuscular methotrexate 12.5 mg/week, oral sulphasalazine 0.5 g b.i.d., indometacin 100 mg suppository at bed-time)
Trial: 11367869
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus antioxidant combination
Trial: 11367869
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of vitamin E (400 mg t.i.d.) plus standard treatment
Trial: 3676625
Drug: Day hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day hospital treatment (psychotherapy)
Trial: 3676625
Drug: Day hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day hospital treatment (all forms of day care)